






























I.  Aging-Associated Diseases and Stem Cell 
Therapy 
 
In 2010, individuals aged 65 years and older constituted 
approximately 12.9% and 8% of the population in the 
United States and worldwide, respectively [1]. This 
number is expected to increase dramatically as millions 
of individuals from the baby boom generation born 
between 1945 and 1964, continue to reach this age. 
Thus, the ability to prevent and treat aging-associated 
diseases is rapidly becoming a primary focus in various 
sectors of the biomedical field.   
 
Aging-associated diseases include degenerative 
conditions affecting tissue and organ function. For 
example, neurodegenerative disorders such as 
Alzheimer’s disease, Parkinson’s disease, and 
amyotrophic lateral sclerosis (ALS) are conditions 
marked by the progressive deterioration of structure and 
function leading to neuronal death. A retinal disorder, 
age-related macular degeneration, is caused by the 
gradual degeneration of cells in the macula of the  retina  
 
 































and is the leading cause of vision loss in adults over age 
55. Conditions such as osteoarthritis and osteoporosis, 
which are marked by the degeneration of cartilage and 
bone, respectively, cause the majority of knee, joint, 
hip, and spine injuries in older individuals. 
 
Aging-associated diseases may also arise from cell 
dysfunction. Such conditions may include cancer, heart 
disease, chronic obstructive pulmonary disease 
(COPD), and diabetes.  Cancer is caused by metabolic 
changes in cells that lead to DNA damage that can fuel 
the uncontrollable and inappropriate proliferation of 
cells. The risk of cancer increases significantly with 
age. Heart disease is typically caused by prolonged 
exposure of the heart to hypertension, 
hypercholesterolemia,
  diabetes, and other 
cardiovascular risk factors, as well as an age-dependent 
increase in the prevalence of left
  ventricular 
hypertrophy, diastolic dysfunction, and atrial fibrillation 
[2]. COPD is a group of progressive diseases of the 
respiratory system that includes emphysema, 
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caused by abnormal mucus production along the 
bronchial airways [3]. In the case of ‘adult-onset’ type 2 
Diabetes, pancreatic islet β-cell function can be 
impaired such that insufficient insulin is produced, or 
cells become resistant to insulin [4].  
 
The prospect of repairing or replacing damaged, 
dysfunctional or missing cells with new functional cells 
has shifted the therapeutic paradigm toward restoring 
tissue function in individuals affected with aging-
associated diseases. The primary candidate for the 
development of these therapies is stem cells, 
particularly human embryonic stem cells (hESC), which 
has the capacity to self-renew indefinitely and 
differentiate into all tissue-specific cell types (Figure 1). 
In this review, we will describe the derivation, 
maintenance, and properties of pluripotent hESCs. We 




































tion of specific cell types from hESCs, with primary 
focus on cell types that are applicable in understanding 
the pathology, as well as a potential source of cell-based 
therapies, in aging-associated diseases. 
 
II.  Human Embryonic Stem Cells: Sources, 
Maintenance, and Common Properties 
 
Human embryonic stem cells (hESCs) are pluripotent 
stem cells derived from various stages of embryonic 
development. hESCs are uniquely capable of 
proliferating indefinitely and differentiating into all 
tissue cell types. The unrestricted potential of hESCs 
has made these cells especially attractive for therapeutic 
applications. In particular, the regenerative capacity of 
hESCs could be the key to successful treatment of 
aging-associated diseases which, as discussed in the 
previous section, are characteristically marked by 





























































































































































  Table 1. Methods for differentiating hESCs into specific cell types for treatment of aging-associated diseases 
 
   Clinical Application  Cell Type  Method  Specific Factors and/or  







associated liver disease 
Hepatocytes  
Differentiation of hESC 
into definitive endoderm, 
followed by sequential 
 exposure to differentiation 
factors 
FGF, BMP4 




Diabetes  Pancreatic Islet 
Progenitors  
Activin A, Wnt3A 






pulmonary disease  Lung Alveolar Cells  
Genetic modification of 
hESCs followed  
by spontaneous 
differentiation 
Recombinant keratinocyte growth 





Prevention and treatment 
of infection, allograft 
rejection, allergic and 
autoimmune diseases, and 
targeting cancer cells 
Dendritic cells  Human embryoid body 
formation 
Serum-free conditions 
BMP4   [102] 
Blood cells  Spin embryoid 
body formation  Serum-free conditions   [41] 
T and NK cells  Co-culture with stromal 
cells 
Co-culture with stromal M210-B4 
cells to enhance expansion of 
CD34
+/CD45
+ progenitors  
[43] 




Human embryoid body 
formation 











on 3D scaffolds 
Co-culture with primary 
chondrocytes 
poly-D, L-lactide scaffold  
[56] 
Heart disease  Cardiomyocytes  
Human embryoid body 
formation 
Serum-free conditions 
























Shh   [66] 
Alzheimer's disease, 
Huntington's disease  Cholinergic neurons  Formation of neurospheres  Shh, FGF8, BMP9  
or LHX8/GBX9 overexpression  [68] 
ALS 
Motor neurons   Formation of 
neural rosettes 
Retinoic acid 
Shh   [67] 
Schwann Cells   Formation of 
neural rosettes 







B27, thyroid hormone 
retinoic acid, FGF2,  







Activin A, nicotinamide   [73] 
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hESCs are typically derived through the microsurgical 
removal of the inner cells mass (ICM) of the blastocyst-
stage pre-implantation embryo (Figure 1). Cells 
populating the ICM are pluripotent, in that they are 
capable of differentiating into the extraembryonic 
endoderm and the three germ layers that form all tissues 
of the embryo: ectoderm, mesoderm, and endoderm. 
Under specific conditions, these cells can proliferate in 
the undifferentiated state in vitro and retain their 
pluripotency indefinitely.  hESCs have also been 
derived and established from single blastomeres of the 
4- or 8- cell embryo [5-8], 16-cell morula [9, 10], or the 
ICM of parthenogenetic embryos. A single blastomere 
is highly totipotent and can generate an entire embryo. 
Thus, hESCs derived from blastomeres circumvent the 
ethical controversies surrounding the use of hESCs, 
since the removal of a single blastomere, in theory, will 
not impede the ability of the remaining blastomeres to 
form a normal embryo. Similarly, parthenogenetic 
embryos, which are generated through artificial 
fertilization of donor oocytes [11-14], have become 
highly desirable sources of hESCs because viable 
embryos are neither created nor destroyed. Furthermore, 
hESCs derived from parthenotes are especially 
attractive because these cells are homozygous for major 
human lymphocyte antigen (HLA) alleles, which could 
help circumvent immunological rejection that may 
occur in hESC transplantation therapies (discussed 
below). Since the initial derivation of pluripotent hESCs 
from ICM by Thomson and colleagues in 1998 [15], 
hundreds of hESC lines have been established from 
various embryonic sources and are now utilized in basic 
and clinical research worldwide. In the United States, 
there are over 80 hESC lines that adhere to federal 




















B.  Cellular and Molecular Properties of 
Pluripotent hESCs 
Pluripotent hESCs maintain specific morphological and 
molecular properties that are shared by the majority of 
hESC lines. Morphologically, single hESCs have an 
enlarged nucleus and distinct nucleoli. In culture, 
proliferating hESCs form compact cell colonies of 
spherical cells (Figure 2). Under differentiation 
conditions, these colonies lose their compact morphology 
and are distinguished by the appearance of flattened cells 
at the edges as differentiating cells begin to migrate out 
of the colony. Spontaneous differentiation of hESCs in 
culture can be controlled with regular supplementation of 
fresh growth medium [17].  
 
A panel of molecular markers has been identified in 59 
independently derived pluripotent hESC lines by the 
International Stem Cell Initiative, a consortium of stem 
cell researchers from more than 15 countries [18]. 
These markers have been routinely used when 
characterizing pluripotent hESCs. These include genes 
with known roles in maintaining pluripotency or other 
developmental processes such as Nanog, POU domain 
class 5 homeobox 1 protein (POU5F/OCT4), 
teratocarcinoma-derived growth factor 1 (TDGF1), 
DNA (cytosine-5-)-methyltransferase 3β (DNMT3β), γ-
aminobutyric acid (GABA) A receptor β3 (GABRB3), 
and growth differentiation factor 3 (GDF4). 
Additionally, pluripotent hESCs express a number of 
surface markers such as Stage Specific Embryonic 
antigens 3 and 4 (SSEA-3, SSEA-4), along with keratin 
sulfates (TRA-1-60, TRA-1-81, GDTM2, and GCT343) 
and protein antigens (CD9 and Thy1). Furthermore, 
hESCs can also be identified based on the expression of 
alkaline phosphatase, stem cell factor (SCF/c-Kit 
ligand), and class 1 HLA proteins. Efforts are ongoing 
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expression is still lacking, several studies have 
identified a number of microRNA clusters prominently 
expressed in hESC lines, some of which have 
established roles in maintaining the pluripotent state of 
hESCs [19, 20]. These include microRNA (miR)-92b, 
miR-302 cluster, miR-200c, miR-368, and miR-154* 
clusters, miR-371, miR372, miR-373*, miR-373, and 
the miR-515 cluster [21, 22]. Pluripotent hESCs also 
display distinct epigenetic properties. Generally, the 
chromatin structure of hESCs is in an open 
conformation that allows transcription factors to enter 
and regulate gene expression [23]. In addition, DNA 
methylation profiles of hESCs are distinguishable from 
other cell types. Markedly reduced methylation patterns 
of CpG dinucleotides are specifically present in the 
promoter regions of pluripotency genes such as OCT4 
and Nanog [24]. These unique epigenetic properties of 
hESCs are necessary to maintain their pluripotent state, 
and can therefore be used as a hallmark of 


































C.  Establishing Pluripotency of hESCs 
hESCs are capable of differentiating into cells that 
constitute the three germ layers. This can be tested 
using established in vivo and in vitro techniques that are 
routinely used to determine pluripotency of a hESC 
line. The most commonly used in vivo method involves 
the induction of teratoma formation after transplantation 
of undifferentiated hESCs into immunodeficient mice 
[25-28]. Teratomas are benign tumors consisting of 
tissue structures derived from the three embryonic germ 
layers (Figure 3). Analysis of teratomas formed from 
engrafted hESCs can be used to determine their 
differentiation potential. The ability of hESCs to 
differentiate into various cell types can also be tested in 
vitro through the formation of embryoid bodies (EBs). 
EBs are spherical colonies of non-adherent, 
differentiating hESCs that contain cell populations 
representative of all three embryonic germ layers. 
Under suitable conditions, EBs can differentiate into 
specific cell types. As will be discussed below, EB 
formation is typically used as an intermediate step when 


































Requirement Methods  of  Testing 
Cell line identity  Short Tandem Repeat (STR) testing 
Human Leukocyte Antigen (HLA) testing 
Sterility and pathogens  Bacteria/fungi/mycoplasma culture 
qPCR analysis for murine viral short interspersed   
     elements (SINE) 
Genetic/chromosomal stability  Single Nucleotide Polymorphism (SNP) analysis 
G-band karyotype analysis spreads  
Fluorescent in situ hybridization 
Epigenetic stability  MicroRNA profiling 
Methylation analysis 
X-inactivation 
Pluripotency Teratoma  formation 
SSEA-3/4, TRA-1-60, TRA-1-81 detection 
Quality and differentiation ability  Gene expression profiling 
qPCR analysis 
Embryoid body formation 
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The most promising feature of hESCs is the ability to 
derive lineage-restricted progenitors that are capable of 
differentiating into specialized post-mitotic cell types 
that can be used in cell-based therapies. Furthermore, 
hESCs provide a virtually inexhaustible source of 
specific cell populations, due to their ability to divide 
indefinitely. Current research studies are focused on 
identifying and refining ways for directing the 
differentiation of hESCs to enrich for pure, homogenous 
populations of specific cell types that can be used to 
either replace damaged cells or coax neighboring cells 
to function properly.  In the following sections, we will 
provide some examples of how differentiation of hESCs 
is directed towards tissue-specific cells, particularly 
those with potential to treat aging-associated diseases.  
 
A.  hESC-Derived Endodermal Cells 
Endodermal derivatives include cells that populate the 
lung, liver, pancreas, urinary bladder, pharynx, thyroid, 
parathyroid, and digestive system. The initial step in 
generating endodermal cells is the formation of 
definitive endoderm. D’Amour et al. [29] showed that 
selective induction of definitive endoderm can be 
achieved through the addition of high concentrations of 
Activin A, under low serum conditions, and in a stage-
specific manner. Activin A mimics the action of Nodal, 
a ligand that activates transforming growth factor-β 
(TGFβ) signaling. The effect of Activin A in inducing 
definitive endoderm is enhanced when additional 
factors are present, such as Wnt3a [30], Noggin [31], or 
when coupled with the suppression of the 
phosphoinositide 3-kinase pathway [32].  
 
The induction of definitive endoderm from hESCs can 
lead to the generation of specific progenitor populations 
such as pancreatic islet β cells, hepatocytes, or alveolar 
epithelial cells. These are being developed with the 
intent of treating diseases such as diabetes, liver disease, 
or lung disease, respectively. Among the most 
successful examples to date is the generation of 
pancreatic islet progenitors devised by Kroon et al. [33] 
through the sequential exposure of hESCs to Activin A 
and Wnt3A, followed by the addition of keratinocyte 
growth factor or FGF7 to induce the formation of the 
primitive gut tube. Subsequently, retinoic acid, 
cyclopamine, and Noggin are added to inhibit Sonic 
Hedgehog (Shh) and TGFβ signaling, and thus induce 
the differentiation of posterior foregut cells, the source 
of pancreatic cell progenitors. These are cultured further 
to generate pancreatic endoderm cells. When these cells 
were engrafted into immunodeficient mice, they 
displayed the histological and structural characteristics 
of pancreatic islet β cells and were able to sustain 
insulin production for at least 100 days. These results 
have been met with great enthusiasm for their potential 
in treating diabetes, type 2 diabetes being the most 
common type affecting more than a quarter of 
individuals aged 65 years or older in the United States 
[34].  
 
In a similar manner, hepatocytes are obtained after 
differentiation of hESCs into definitive endoderm [35, 
36]. A highly robust population of functional 
hepatocytes was generated with the sequential addition 
of low serum media, collagen I matrix, and hepatic 
differentiation factors that include FGF, BMP4, 
hepatocyte growth factor, oncostatin M, and 
dexamethasone [36]. These cells expressed known 
markers of mature hepatic cells, exhibited appropriate 
function, and were able to integrate and differentiate 
into mature liver cells when injected into mice with 
liver injury. The ability to differentiate hepatic cells 
could prove useful in the treatment of a number of liver 
diseases that are prevalent in aging individuals, such as 
cirrhosis, hepatocellular carcinoma, and diabetes-
associated chronic liver disease [37]. 
 
The use of hESCs to treat lung injury has also been an 
area of active investigation. A significant step towards 
directed differentiation of lung-specific cells was 
reported by Wang et al. [38, 39], in which genetically 
modified hESCs carrying lung-specific reporters under 
the control of promoters from tissue-specific genes such 
as surfactant protein C, aquaporin 5 and T1α, resulted in 
purification of type I and type II alveolar epithelial 
cells. When engrafted into mice suffering from acute 
lung injury, these cells exhibited functional properties 
including the capacity for gas exchange and histological 
amelioration of lung injury.  
 
B.  hESC-Derived Mesodermal Cells 
Directing the differentiation of hESCs into mesoderm 
requires the activation of the TGFβ signaling pathway 
and can be accomplished through the stepwise and 
dosage-dependent addition of Activin A, BMP4, and 
growth factors, such as vascular endothelial growth 
factor (VEGF) and basic FGF (bFGF) [40]. Mesodermal 
derivatives have also been successfully obtained by 
spontaneous differentiation of hESCs through hEB 
formation without first directing them toward 
mesoderm. Robust differentiation of hESCs into 
hematopoietic lineage cells, which give rise to all blood 
cell types and components of the immune system, has 
been achieved under serum-free conditions through spin 
hEB formation [41]. Specific hematopoietic lineage cell 
types, such as functional dendritic cells, have been 
successfully differentiated from hESCs through 
spontaneous hEB formation under serum-free 
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points [42]. Hematopoietic progenitor cells that give 
rise to functional T and natural killer cells capable of 
targeting human tumor cells both in vitro and in vivo, 
have also been derived from hESCs co-cultured with 
stromal cells [43]. Thus, the ability to differentiate 
hESCs into hematopoietic lineage cells promises to be 
useful in improving existing therapies that require blood 
cell transplantation, in fighting cancer, and in immune 
therapies that require induction of the immune response 
in an antigen-specific manner [44].   
 
Cardiomyocytes, which represent another 
therapeutically important derivative of mesoderm, have 
been successfully generated from hESCs using several 
methods [45]. Through hEB formation, hESCs can 
spontaneously differentiate into cardiomyocytes under 
appropriate culture conditions. These cardiomyocytes 
exhibit morphological, molecular, and electro-




































  [46], and display quantifiable responses to 
physiological stimuli reminiscent of atrial, ventricular, 
and pacemaker/conduction tissue [47-50]. 
Cardiomyocytes have also been generated by directed 
differentiation with Activin A and BMP4 on a dense 
monolayer of hESCs; these cells successfully form 
functional cardiomyocytes when transplanted in vivo 
[51]. Another study used additional medium 
supplements that included VEGF, and the Wnt 
inhibitor, Dickkopf homolog (DKK1), followed by the 
addition of bFGF, to promote cardiomyocyte 
differentiation from hEBs [52]. Success of these 
studies was measured by the expression of proteins 
specific for mature cardiac cells such as cardiac 
troponin T, atrial myosin light chain 2, and the cardiac 
transcription factors, Tbx5 and Tbx20. Several groups 
have generated cardiac-specific reporter hESC lines 
that can be used to test various differentiation 












































epithelium.  (C)  Cartilage  surrounded  by  capsule  of  condensed  mesenchyme.  (D)  Glandular
intestinal structure. (E) Nascent neural tube. (F) Primitive squamous epithelium. Bar, 100 µm. 
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or cartilage, as can be appreciated from teratoma 
formation assays (Figure 3). Thus, hESCs may be a 
valuable source of cells suitable for connective tissue 
replacement therapy for diseases such as osteoarthritis 
and osteoporosis, which are characterized by the 
breakdown of cartilage in joints and pathological 
fractures due to low bone density, respectively. Most 
successful and efficient protocols for directing 
chondrocyte differentiation from hESCs utilize 3D 
culture systems created by seeding hESCs at high 
density leading to formation of a pellet, or by 
introducing the cells into a synthetic 3D scaffold. Such 
systems enable cell-cell signaling between the 
undifferentiated hESCs and mature chondrocytes to 
stimulate homogeneous and sustained chondrogenic 
differentiation. For example, single-cell suspension of 
dissociated hEBs cultured as high-density micromass 
with BMP2 facilitates chondrocyte formation [54]. 
hESCs co-cultured with primary chondrocytes or in the 
presence of osteogenic supplements and polymeric 
scaffolds yield cartilaginous- or osteogenic-like cells 
[55, 56]. More recently, feeder-free 3D culture systems 
have successfully derived multipotent connective tissue 
progenitors from hESCs yielding tendon-like structures. 
The engraftment of these in vitro differentiated tendon 
structures in injured immunosuppressed mice restored 
ankle joint movements that rely on an intact Achilles 
tendon [57]. Furthermore, there is evidence to suggest 
that cell transplantation promotes growth and repair 
through endogenous cells as well [58].   
 
C.  Ectodermal Derivatives of hESCs 
The dominant differentiation pathway in hESC cultures 
leads to the formation of ectoderm, which gives rise to 
cells of the nervous system and the epidermis.  hESC-
derived neural progenitor cells are characterized by 
rosette-like neural structures that form in the presence 
of  FGF2 or EGF through either spontaneous 
differentiation from an overgrowth of hESCs, or after 
hEBs are plated onto adherent substrate [59, 60]. These 
‘neural rosettes’ have become the signature of hESC-
derived neural progenitors capable of differentiating 
into a broad range of neural cells in response to 
appropriate developmental signals. Thus, many studies 
are exploring ways to enhance the formation of neural 
rosettes to generate enriched populations of specific 
neural cell types. One example is the use of stromal cell 
lines [61], which provides ectodermal signaling factors 
required for neural induction, and promotes the 
formation of neural rosettes [62, 63].  
 
The withdrawal of FGF2 and EGF, and addition of 
other factors can lead to the differentiation of neural 
rosettes into specific neural subtypes. Neural crest stem 
cells derived from neural rosettes can differentiate into 
peripheral sympathetic and sensory neurons through the 
addition of BDNF, GDNF, NGF and dbcAMP, or into 
Schwann cells in the presence of CNTF, neuregulin 1β 
and dbcAMP [64]. Neuroglial cells, such as 
oligodendrocytes, are generated with B27, thyroid 
hormone, retinoic acid, FGF2, epidermal growth factor, 
and insulin [65]. Additionally, FGF8 and Shh induce 
hESC-derived neural progenitors to differentiate into 
dopaminergic neurons [66], while treatment with Shh 
and retinoic acid induce motor neuron differentiation 
[67]. Recently, functional basal forebrain cholinergic 
neurons have been derived from hESCs through the 
formation of neurospheres and subsequent exposure to 
Shh, FGF8, and BMP9, or by overexpression of LHX8 
and GBX9 [68]. 
 
The ability to differentiate hESCs into neuronal and 
non-neuronal subtypes has generated much interest due 
to their potential use in drug testing or cell replacement 
therapies for a number of neurodegenerative diseases. In 
particular, the successful derivation of dopaminergic 
neurons, particularly those of the midbrain subtype, 
could potentially be used to treat Parkinson’s disease, 
which is marked by the progressive loss and 
dysfunction of these neurons. In Alzheimer’s disease, 
where the degeneration of basal forebrain cholinergic 
neurons causes debilitating cognitive dysfunction, 
hESC-derived cholinergic neurons may also be useful 
for therapy. However, hESCs may also be helpful 
without requiring cell replacement. As observed in a 
clinical trial in which autologous fibroblasts 
programmed to express human NGF were implanted in 
the forebrain of individuals with mild Alzheimer’s 
disease, a marked improvement in the rate of cognitive 
decline was observed [69]. One can imagine exploiting 
genetically-modified hESC-derived neuronal 
progenitors that readily engraft and express therapeutic 
gene products, such as NGF, to prevent the 
degeneration of cholinergic neurons in the basal 
forebrain. 
 
Similarly, hESC-derived motor neurons might be used 
in the treatment of ALS, which is characterized by the 
progressive loss of motor neurons in the cortex, brain 
stem, and the spinal cord. Studies of ALS disease 
models have also suggested that non-neuronal cells, 
such as oligodendrocytes and Schwann cells, may be 
involved in the pathogenesis of this disease [70, 71]. 
Thus, the ability to differentiate hESCs into both 
neuronal and non-neuronal cells of the central nervous 
system provides an attractive therapeutic approach.  
 
The efficacy of transplanting hESC-derived 
oligodendrocytes to treat acute spinal cord injury is now 
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approved by the United States Food and Drug 
Administration (FDA) [72]. Oligodendrocytes are 
rapidly lost during acute spinal cord injury leading to 
demyelination and neuronal loss. In a trial sponsored by 
Geron Corporation, purified oligodendrocyte progenitor 
cells derived from hESCs will be injected into the spinal 
cord of paralyzed patients within two weeks after 
injury. While this first trial is a safety study, the 
expectation is that these progenitor cells will terminally 
differentiate into oligodendrocytes and produce myelin, 
which insulates neuronal cell membranes and is critical 
for efficient conduction of neuronal impulse 
transmission. If successful integration and function of 
oligodendrocytes is achieved in these studies, it could 
lead the way toward new treatment approaches for ALS, 
which manifests in demyelination of degenerating 
motor neurons.   
 
Retinal pigment epithelium (RPE) cells are another 
specific cell type derived from neuroectoderm. RPE 
cells support the neural retina by phagocytosing and 
renewing the photoreceptor outer segments of 
rhodopsin. Recent reports have shown that RPE can be 
induced from hESCs in the presence of nicotinamide 
and Activin A under serum-free conditions [73]. hESC-
derived pigmented cells exhibit the morphological and 
functional properties of RPE cells after transplantation 
in an animal model of macular degeneration, a disease 
caused by dysfunction and loss of RPE. These data have 
led to the second and third FDA-approved clinical trials 
using hESCs, these sponsored by Advanced Cell 
Technology. For these trials, hESC-derived RPEs will 
be transplanted directly into the degenerating retinae of 
patients with Stargardt’s Macular Dystrophy, a juvenile 
form of macular degeneration, or Dry Age-Related 
Macular Degeneration, to rescue visual acuity. The 
launch of these three clinical trials heralds the 
translation of hESC research into therapy for 
degenerative disease, and the fields of stem cell biology 
and geriatric medicine await the results with great 
anticipation. 
 
IV.  Current Challenges and Potential Solutions 
for the Therapeutic Use of hESC-Derived Cells 
 
Cellular therapies involving hESCs are in development 
and have begun to enter clinical trials. The 
International Stem Cell Banking Initiative (ISCBI) has 
been created by the International Stem Cell Forum, a 
group of national and international stem cell research 
funding bodies, to develop a set of best practices and 
principles for banking, testing, and distributing hESCs 
for therapy [74]. In the United States, the FDA also 
monitors these guidelines and have issued 
recommendations for reviewers of proposals for stem 
cell therapeutic trials [75]. It is important to note that 
these recommendations do not ensure the quality or 
efficacy of hESC-derived cells used for clinical 
applications. Rather, these guidelines warrant that the 
cells used for therapy are reproducible and meet 
specific criteria to ensure patient safety (Table 2). The 
major safety concerns for the use of hESCs are 
discussed in the following sections.   
 
A.  Xenobiotic-Free Conditions 
Many of the hESC lines currently in use have been 
exposed to animal products during isolation and 
propagation of hESCs in vitro. Under these conditions, 
hESCs could possess animal viruses and other unknown 
substances capable of eliciting a detrimental immune 
response in transplanted hosts. Currently, hESC lines 
under development for clinical use undergo extensive 
microbiological testing as strictly recommended by 
ISCBI. In the United States, the FDA legally requires 
documentation of the source, the potential genetically 
modified components, and pathogenic agents in any 
hESC-derived cell intended for therapeutic use. Thus, 
avoiding exposure to xenobiotics is an ongoing effort. 
Recently, replacement media have been developed that 
would allow maintenance of hESCs in xenobiotic-free 
conditions. These include xenobiotic-free serum 
replacements such as Knockout Serum Replacer 
(Invitrogen) or xenobiotic-free culture media such as 
HESGRO (Millipore) or TeSR (STEMCELL).  
 
Feeder-free culture systems are now being developed to 
reduce the risk of contamination with foreign agents 
when hESCs are cultured on feeder cell layers. Feeder-
free and xenobiotic-free defined culture media that 
consist of a combination of recombinant growth factors 
known to inhibit differentiation and maintain hESCs in 
the pluripotent state are now commercially available. 
However, some reports have associated feeder-free 
culture conditions with greater chromosomal instability 
and an increased risk of propagating genetically altered 
hESCs [76]. For this reason, most hESC labs practice a 
surveillance program for genomic instability in cultured 
lines [28, 49]. 
 
hESC lines derived using human feeder cells have also 
been reported. For example, hESC lines have been 
successfully derived on human fibroblasts generated 
from neonatal foreskin [77, 78] and adult skin 
fibroblasts [79]. Some laboratories deriving new lines 
have moved exclusively to xenobiotic-free conditions 
[80]. The ability to derive and maintain new hESC lines 
using human fibroblast feeder cells represents a 
significant step towards generating clinical-grade 
hESCs. 
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The best characterized hESC lines to date are among the 
earliest lines derived. However, they may not be the 
best lines for therapeutic application as many of these 
lines were derived using animal products.   
Chromosomal and genomic instability has been detected 
in several hESC lines, with acquisition of loss of 
heterozygosity or copy-number variation in cancer-
related genes [81, 82]. Many of these mutations 
appeared to be induced by prolonged culture, since 
these changes were not observed in low passage cells. It 
has been proposed that such karyotypic aberrations 
occurred with adaptation to the original culture 
conditions used when the first few lines were being 
derived and expanded [83]. These observations 
emphasize the need for complete characterization of 
hESC lines, particularly the effects of long-term culture, 
and the design of guidelines for designating therapeutic-
grade hESCs. 
 
C. Enrichment, Directed Differentiation, and 
Purification of hESC-Derived Cells 
A primary safety concern when using pluripotent 
hESCs is their potential to form germ layer tumors. As 
discussed above, in vivo transplantation of 
undifferentiated hESCs in mouse models results in 
teratoma formation. Evidence of tumor formation has 
also been observed in differentiated hESC derivatives 
transplanted in vivo [84, 85]. Thus, it is essential that 
candidate hESC derivatives intended for use in cell 
transplantation are free of tumorigenic cells. Another 
concern is the differentiation of hESC-derived cells into 
unwanted cell types. For example, the engraftment of 
inappropriate muscle cells into damaged myocardium 
could alter the electrical activities of recipient tissue, 
provoking arrhythmias [86]. Thus, developing and 
further optimizing differentiation and purification 
protocols are necessary to minimize the generation of 
unwanted cell types for pre-clinical transplantation 
experiments and clinical therapy.  
 
As discussed earlier, enrichment of specific cell types 
can be achieved using molecules introduced at critical 
time points during culture. However, many of these 
methods yield only moderate enrichment that is not yet 
scalable for clinical application. It may be desirable to 
enrich first for partially differentiated, proliferative 
hESC intermediates with specific cell fates. These could 
then be expanded before further differentiation into 
cells for therapy.  For example, the expression of the 
cell surface antigen, CD133, on proliferating hESCs 
identifies cells predestined toward a neuroectodermal 
fate [26]. CD133-positive cells have been selected from 
cultures of undifferentiated hESCs, and have been 
observed to differentiate primarily into neuroectodermal 
cells in vitro and in vivo [26].  
 
In the absence of specific cell surface antigens like 
CD133 to identify tissue-specific precursors, molecular 
beacons have been used to select for specific 
subpopulations of hESCs. King et al. [25] first 
demonstrated the utility of this system for isolating 
viable Oct4-expressing pluripotent hESCs in a specific 
and high-throughput manner. Molecular beacons are 
single-stranded oligonucleotides that generate 
fluorescent signals when bound to their target mRNAs, 
making these cells detectable and selectable by 
fluoresence-activated cell sorting. More importantly, 
molecular beacons have a short lifespan within cells and 
do not alter the function or genomic structure of hESCs. 
Thus, this method can be used to enrich for desired 
hESC-derived cell populations or used to select against 
unwanted cell types, such as undifferentiated hESCs 
that could form tumors [25].  
 
D. Circumventing Immune Rejection of Transplanted 
hESC-Derived Cells 
Transplanted hESCs encounter immune rejection [87] 
because both proliferating and differentiated hESCs 
express class I and II HLA as well as minor 
histocompatibility antigens at levels sufficient to 
activate the immune system [87, 88]. Another potential 
barrier to hESC engraftment can occur through 
mismatch between hESC donor and recipient ABO 
blood group antigens [89-91]. While studies to 
determine the effects of ABO incompatibility on hESC 
transplantation are still lacking, this has long been a 
criterion for successful organ transplantation and thus, it 
is likely that ABO incompatibility between hESC-donor 
cells and the recipient would also trigger immune 
rejection.  
 
Ideally, having genetically identical donor and patient 
cells is the best way to circumvent immune rejection. 
Thus, there is expressed interest in developing and 
using somatic cell nuclear transfer to generate patient-
specific hESC lines. Using this technique, the DNA 
obtained from either a patient’s skin or muscle cell 
would be transferred into an unfertilized egg that has 
had its DNA removed. Subsequently, the egg is 
artificially fertilized and allowed to develop until it 
reaches the blastocyst stage to derive hESCs. The 
resultant hESC line would have an immunologic profile 
matching the patient and could be used for cell therapy. 
This technique has been conducted successfully in 
animals using species-specific ESCs, but derivation of 
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match to potential transplant patients include 
engineering “universal donor hESCs,” a blood antigen 
O cell in which the expression of HLA is suppressed, or 
chimeric hematopoietic cells derived from hESCs 
capable of inhibiting the immune response when co-
transplanted with the desired hESC-derived cells [92]. 
Alternatively, creating banks of hESC lines representing 
HLA/ABO combinations that match the majority of 
potential patients has been proposed. Studies have 
provided estimates on how many hESC lines would be 
needed in order to support the needs of a specific 
population.  Taylor et al. [93] estimated that 
approximately 150 hESC lines could provide an HLA 
match for most of the population in the United 
Kingdom. Alternatively, approximately 10 parthenote-
derived hESC lines that are homozygous for HLA types 
could be sufficient for a majority of the population. 
Studies by Nakajima et al. [94] estimated that 
approximately 170 hESC lines, or 55 hESC lines with 
homozygous HLA types, would be sufficient for 80% of 
patients in the Japanese population. These findings 
demonstrate the feasibility of creating and maintaining a 
hESC bank with sufficient representation to support a 
large number of patients. However, in countries such as 
the United States, many more hESC lines would need to 
be established to serve its ethnically and genetically 
diverse population. Given the ethical issues and 
restrictions on hESC research, and the small number of 
approved hESC lines currently available, the creation of 
a hESC bank with a highly diverse collection of cell 
lines will undoubtedly face enormous challenges.  
 
V.  Therapeutic Advantages of hESCs Over 
Other Stem Cell Sources 
 
While not the focus of this review, other sources of 
human-derived stem cells are also being explored for 
use in clinical settings. Among these are adult stem cells 
and induced pluripotent stem cells (iPSCs). Unlike 
hESCs, these stem cells can be obtained directly from 
the individual to be treated. Thus, as a source of cells 
for therapy, they are able to circumvent the 
immunocompatibility issues that hamper many non-
autologous transplantation therapies. Furthermore, the 
utilization of these stem cells in both clinical and basic 
research studies does not face ethical and political 
issues that otherwise surround the use of embryonic 
stem cells. However, adult stem cells and iPSCs have 
significant limitations as well that are potentially 
overcome by hESCs at this time. 
 
Adult stem cells are derived from non-embryonic 
tissues and typically reside in their tissue of origin. 
Similar to hESCs, adult stem cells are capable of self-
renewal. However, unlike hESCs, they have restricted 
potential and are able to differentiate only into cells 
from the tissue of origin. In some cases, adult stem cells 
are not able to generate all cell types of the tissue of 
origin, nor can they sustain growth over time. The latter 
problem has been encountered specifically in stem cells 
obtained from aging individuals [95, 96].  
 
iPSCs are generated by reprogramming differentiated 
somatic cells into a pluripotent state. This can be 
achieved by inducing the expression of three core 
reprogramming factors Oct4, Sox2, and Nanog. Several 
methods have been employed to express these factors 
and induce pluripotency. Among these are retroviral, 
lentiviral, and adenoviral transduction, which carry the 
risk of permanent and harmful genomic integration. 
Indeed, some established iPSC lines are genetically 
unstable, exhibiting large-scale genomic 
rearrangements, copy number variations, and abnormal 
karyotype even in early passage stages [97, 98]. To 
minimize the possibility of mutagenesis caused by 
methods used to introduce the reprogramming factors, 
integration/plasmid-free strategies have been employed 
to express these factors and induce pluripotency such as 
synthetic RNA delivery, RNA virus transduction, or the 
addition of cell-penetrating purified recombinant 
proteins [99, 100]. However, these methods are 
significantly less efficient at generating reprogrammed 
pluripotent cells in comparison to viral integration. 
Furthermore, in some iPSC lines reprogrammed using 
non-integrating viral method, high levels of mutational 
changes were still observed [97].  
 
In addition to genomic changes, recent studies have also 
revealed that iPSCs contain epigenetic features that 
indicate either incomplete or aberrant reprogramming. 
In particular, iPSC DNA methylation patterns are 
frequently reminiscent of the somatic cell of origin 
[101], suggesting that iPSCs are not completely 
reprogrammed into the naïve pluripotent state seen in 
hESCs. It is unclear whether the observed genetic 
instability and epigenetic imprinting accrued during 
reprograming or was present in the somatic cell of 
origin. Nevertheless, patient-specific iPSCs may be less 
suitable for the treatment of aging-associated diseases, 
since somatic cells from older individuals are more 
likely to contain genomic mutations and 
disadvantageous epigenetic programs. Thus, the safety 
and efficacy of therapeutic iPSCs as currently derived 
remain to be tested.  
  
VI.  Conclusions 
 
As cell replacement therapies are envisioned and 
realized, their use in the treatment of aging-associated 
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provide much promise as a potential tool in designing 
such therapies, as well as in drug discovery. It is clear 
that there are still major scientific challenges as well as 
ethical and legislative issues that must be addressed. 
However, it is encouraging to see that clinical trials 
involving the use of hESCs have begun, and that 
extensive efforts are underway to efficiently, 
successfully, and safely differentiate hESCs into 
specific cell types. These studies will pave the way 
toward leveraging the therapeutic benefit of hESCs for 
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